Titus Thorne

Last Updated April 1, 2022

Titus Thorne

 April 1, 2022

Peptide researchers curious about tesamorelin side effects will be pleased to know that this reference material is generally considered to be safe and well-tolerated. 

But there are still a whole host of safety concerns that researchers could consider before administering this peptide to test subjects. 

This guide will outline all known tesamorelin side effects and explain what this peptide is, the benefits it offers, and which side effects researchers should be aware of when conducting experiments or trials. 

As a bonus, researchers will also find a complete guide to our preferred tesamorelin vendor at the end of this guide. 

Let’s go!

Buy Tesamorelin from the #1 online Peptides vendor in the world...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.


What is Tesamorelin?

Tesamorelin peptide is a synthetic compound made up of a sequence of amino acids [1]. There are thousands of peptides in the body and they work together as chemical signals to regulate various functions [2].

Tesamorelin has a structure that is virtually identical to one of the body's natural peptide hormones called growth hormone-releasing hormone (GHRH) [3]. GHRH has one specific function: helping to upregulate human growth hormone (HGH).

What is HGH?

HGH is a hormone that is essential to all tissue growth and repair processes that happen throughout the body. It is involved in everything: building muscle, bone growth, replacing collagen in the skin, even healing wounds, and more [4].

But HGH levels in the body naturally decline with age [5].

Research has found that exogenous HGH therapy can have a number of positive benefits like helping increase lean muscle mass and decrease body fat in test subjects [6]. But there are significant downsides to supplementing HGH directly; it has been linked to serious side effects [7].

Tesamorelin HGH Supplementation

Researchers have found that it is much safer to increase HGH levels in the body indirectly by using peptides that cause the body to produce and secrete more of its own, natural HGH. Tesamorelin can do just that.

Tesamorelin, since it looks like GHRH, can bind to the same receptors that GHRH does. When it binds to receptors in the pituitary gland, which is responsible for synthesizing and secreting HGH, it signals the gland to produce more HGH.

The primary effect of tesamorelin is to increase levels of HGH in the body. But what about its other benefits? We’ll explore those in the following section.


tesamorelin


Tesamorelin Benefits

Research has linked tesamorelin to numerous benefits.

Its main benefit is that it increases HGH levels [8, 9]. There's no comparison between tesamorelin before and after in terms of HGH levels.

But there are several other benefits of tesamorelin that occur indirectly as a result of raising blood HGH levels.

These benefits of Tesamorelin HGH include:

  • Burning fat [310, 11]
  • Increasing lean muscle (many researchers are studying tesamorelin for bodybuilding) [12].
  • Improving cognition [13, 14, 15].
  • Repairing nerve damage [16].
  • Reducing the risk of Cardiac disease [11, 17].

Is Tesamorelin legal?

It offers many benefits, but is tesamorelin legal?

Yes. It was approved by the FDA as a prescription medication for people with lipodystrophy. But it's also legal for researchers to buy tesamorelin online for research purposes.


Tesamorelin Side Effects | What Researchers MUST Know

Now to the core of this article: Tesamorelin side effects.

Tesamorelin is safe for most test subjects

Research has shown that tesamorelin is generally considered safe and well-tolerated when administered to test subjects. Virtually all research conducted on tesamorelin peptide has concluded that it's safe and produces no serious side effects [3, 11, 18, 19, 20, 21, 22].

But some side effects can occur, so let's take a look.

Tesamorelin side effects

Research has linked tesamorelin to some side effects. From the most common to the least common, they include [23]:

  • Injection site reactions, like pruritus, rash, pain, and swelling (3.1%)
  • Arthralgia (2.4%)
  • Pain in the extremities (1.1%)
  • Myalgia (1.1%)
  • Peripheral edema (1.1%)
  • Paresthesia (0.9%)
  • Hypoesthesia (0.7%)
  • Rash (0.7%)
  • Dysepsia (0.3%)
  • Muscle pain (0.3%)
  • Pruritus (0.3%)
  • Vomiting (0.3%)
  • Muscle stiffness (0.3%)
  • Carpal Tunnel Syndrome (0.2%)
  • Joint swelling (0.2%)
  • Night sweats (0.2%)
  • Palpitations (0.2%)

Use in specific populations

In addition to the adverse effects listed above, researchers must be extra cautious when administering tesamorelin to test subjects in the following populations:

  • Individuals with hypothalamic-pituitary axis issues. Tesamorelin works on the body through the pituitary gland, so it should not be administered to test subjects with disorders that disrupt that system. This includes test subjects with hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or even head trauma [23].
  • Individuals with active malignancy. Test subjects with existing cancer tumors should be excluded from experiments or trials involving tesamorelin.
  • Pregnant women. Tesamorelin should not be administered to pregnant test subjects. There is some concern that burning visceral adipose tissue in the belly could cause harm to the fetus [23].
  • Children. The safety and effectiveness of tesamorelin for use in children hasn't been established, so it should not be administered to test subjects from this population [23].

Researchers should also keep in mind that the safety of tesamorelin has not been studied in older adults and seniors, or individuals with kidney or liver impairments. Test subjects in these groups should be screened for the above-cited issues before being included in experiments or studies involving tesamorelin. 

Tesamorelin and Cancer?

There is currently no evidence linking tesamorelin use to any form of cancer.

However, there is a concern (as with all substances that increase HGH) that tesamorelin could increase the speed of the growth of malignant tumors if those tumors already exist [23]. This is because HGH speeds up tissue growth—including cancerous tissue growth.

For that reason, tesamorelin should not be used by test subjects that suffer from an active malignancy. Individuals with a history of malignant tissues should be excluded from any experiments or studies involving tesamorelin. 

Tesamorelin, Glucose Intolerance, and Diabetes

One further caution is warranted for test subjects with glucose or insulin sensitivities, including those with diabetes or prediabetes.

Research has found that tesamorelin can increase glucose intolerance [23]. Some research even suggests that tesamorelin could increase the risk of developing diabetes [23].

For that reason, test subjects with glucose intolerance should not participate in tesamorelin research.


Where to Buy Tesamorelin Online? | 2022 Guide

In our team’s opinion, the best place for researchers to buy tesamorelin online is Peptide Sciences.

We have been dealing with Peptide Sciences for years and they’ve earned our trust as a reliable, honest vendor. They ship research-grade tesamorelin within a reasonable time frame and charge reasonable prices. 

In our experience, Peptide Sciences offers:

  • High-quality products. They get regular laboratory analyses conducted on their peptides and post them right on the website where researchers can evaluate the purity of the product before making a purchase.
  • Convenient payment options. There are several options for payment, including most major credit cards and various forms of cyber currency. Their payment system is encrypted so researchers will feel comfortable that their information will not be stolen.
  • Fast shipping. Peptide Sciences is an American company, so US-based researchers should receive their orders within 2-3 days. For researchers based overseas, it could take up to 10 days to receive an order, but that's still quite fast. All US orders over $100 ship free.
  • Great customer service. Honestly, we love that you can reach Peptide Sciences if you have an issue. In our experience, they're quick to offer refunds or reships any time there is an issue with the product or an order. This gives researchers peace of mind that they will actually get what you paid for.

Peptide Sciences is our number 1 recommendation for a reliable tesamorelin vendor and we strongly encourage researchers to contact them for the best deals.

Buy Tesamorelin from our #1 recommended vendor...


Side Effects of Tesamorelin? | Verdict

Researchers interested in experimenting with tesamorelin will be encouraged to know that this reference material can be safely administered to test subjects. This guide has highlighted certain populations who must be screened from tesamorelin research, including:

  • Individuals with hypothalamus or pituitary gland issues
  • Individuals with a malignant tumor
  • Pregnant women
  • Children.

Is tesamorelin safe?

Yes. Virtually all research involving tesamorelin has shown that this peptide is safe for most test subjects. The most common tesamorelin side effects affect less than three percent of test subjects.  

Researchers keen on pursuing tesamorelin research are advised to contact Research Peptides.


tesamorelin


References

  1. Food and Drug Administration (2010). Chemistry Reviews: Application 22-505. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s0
    00ChemR.pdf
  2. Mine, Y., Li-Chan, E., & Jiang, B. (2010). Biologically active food proteins and peptides in health: an overview. Bioactive proteins and peptides as functional foods and nutraceuticals. Hoboken: Wiley‑Blackwell, 5-11.
  3. Dhillon, S. (2011). Tesamorelin. Drugs, 71(8), 1071-1091.
  4. Bergan-Roller, H. E., & Sheridan, M. A. (2018). The growth hormone signaling system: Insights into coordinating the anabolic and catabolic actions of growth hormone. General and Comparative Endocrinology, 258, 119-133.
  5. Bartke, A. (2019). Growth hormone and aging: Updated review. The World Journal of Men's Health, 37(1), 19-30.
  6. Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989). Beneficial effects of growth hormone treatment in GH-deficient adults. The Lancet, 333(8649), 1221-1225.
  7. Anderson, L. J., Tamayose, J. M., & Garcia, J. M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: pharmacological basis, methods of detection, and adverse effects. Molecular and cellular endocrinology, 464, 65-74.
  8. Editorial, A. (2004). Pralmorelin: GHRP 2, GPA 748, Growth Hormone-Releasing Peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R & D, 5, 236-239.
  9. Broglio, F., Boutignon, F., Benso, A., Gottero, C., Prodam, F., Arvat, E., … & Muccioli, G. (2002). EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. Journal of Endocrinological Investigation, 25(8), RC26-RC28.
  10. Sivakumar, T., Mechanic, O. J., Fehmie, D. A., & Paul, B. T. (2011). Growth hormone axis treatments for HIV‐associated lipodystrophy: a systematic review of placebo‐controlled trials. HIV medicine, 12(8), 453-462.
  11. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380-389.
  12. Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., … & Brown, T. T. (2019). The Growth Hormone Releasing Hormone analog, Tesamorelin, decreases muscle fat, and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3), 154-159.
  13. Zdravkovic, M., Søgaard, B., Ynddal, L., Christiansen, T., Agersø, H., Thomsen, M. S., … & Ilondo, M. M. (2000). The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Hormone & IGF Research, 10(4), 193-198.
  14. Friedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., … & Vitiello, M. V. (2013). Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging. JAMA Neurology, 70(7), 883-890.
  15. Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology, 69(11), 1420-1429.
  16. Tuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., … & Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert opinion on therapeutic targets, 20(10), 1259-1265.
  17. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., … & Turner, R. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
  18. Zdravkovic, M., Christiansen, T., Eliot, L., Agersoe, H., Thomsen, M. S., Falch, J. F., … & Ilondo, M. M. (2001). The pharmacokinetics, pharmacodynamics, safety, and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Hormone & IGF Research, 11(1), 41-48.
  19. Svensson, J., Monson, J. P., Vetter, T., Hansen, T. K., Savine, R., Kann, P., … & Ilondo, M. M. (2003). Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clinical Endocrinology, 58(5), 572-580.
  20. Zdravkovic, M., Olsen, A. K., Christiansen, T., Schulz, R., Taub, M. E., Thomsen, M. S., … & Ilondo, M. M. (2003). A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. European Journal of Clinical Pharmacology, 58(10), 683-688.
  21. Piccoli, F., Degen, L., MacLean, C., Peter, S., Baselgia, L., Larsen, F., … & Drewe, J. (2007). Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. The Journal of Clinical Endocrinology & Metabolism, 92(5), 1814-1820.
  22. Luzi, L., Meneghini, E., Oggionni, S., Tambussi, G., Piceni-Sereni, L., & Lazzarin, A. (2005). GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. European Journal of Endocrinology, 153(6), 781-789.
  23. FDA (n.d.). Highlights of Prescribing Information: Egrifta. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505Orig1s010lbl.pdf

Table of Contents
    Add a header to begin generating the table of contents